Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL27493617 | 0.99 | ALDH1A1 (0.43) | ALDH1A1MAPK1L3MBTL1SYKKMT2A | |
| SCHEMBL27711717 | 0.92 | ALDH1A1 (0.44) | ALDH1A1MAPK1L3MBTL1SYKKMT2A | |
| SCHEMBL27711718 | 0.92 | ALDH1A1 (0.44) | ALDH1A1MAPK1L3MBTL1SYKKMT2A | |
| Ammonia Solution, Strong SCHEMBL27780858 | 0.91 | ALDH1A1 (0.43) | ALDH1A1MAPK1L3MBTL1SYKKMT2A | |
| SCHEMBL11169957 | 0.90 | ALDH1A1 (0.45) | ALDH1A1MAPK1L3MBTL1SYKKMT2A | |
| SCHEMBL27703130 | 0.90 | ALDH1A1 (0.45) | ALDH1A1MAPK1L3MBTL1SYKKMT2A | |
| SCHEMBL27516607 | 0.89 | ALDH1A1 (0.44) | ALDH1A1MAPK1L3MBTL1SYKKMT2A | |
| SCHEMBL27847368 | 0.86 | ALDH1A1 (0.46) | ALDH1A1MAPK1L3MBTL1SYKKMT2A | |
| SCHEMBL27341323 | 0.86 | ALDH1A1 (0.46) | ALDH1A1MAPK1L3MBTL1SYKKMT2A | |
| SCHEMBL6016191 | 0.86 | ALDH1A1 (0.46) | ALDH1A1MAPK1L3MBTL1SYKKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1420681-B1 | PEPTIDE-BASED MULTIMERIC TARGETED CONTRAST AGENTS | EPIX PHARM INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-7927581-B2 | For magnetic resonance imaging (MRI); peptide modified at its N- and its C-termini, independently, with a moiety comprising a metal chelate complex; specific binding affinity for fibrin; sufficient half-life in vivo | Factor 1A, LLC (US) | 2011-04-19 | — | — | US | disclosed |
| EP-1420681-A4 | PEPTIDE-BASED MULTIMERIC TARGETED CONTRAST AGENTS | EPIX PHARM INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20070185311-A1 | Peptide-Based Multimeric Targeted Contrast Agents | EPIX PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-7238341-B2 | Peptide-based multimeric targeted contrast agents | EPIX PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20060039861-A1 | Peptide-based multimeric targeted contrast agents | EPIX MEDICAL, INC., A DELAWARE CORPORATION | 2006-02-23 | — | — | US | disclosed |
| US-6991775-B2 | Peptide-based multimeric targeted contrast agents | EPIX MEDICAL, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-20050074411-A1 | Peptide-based multimeric targeted contrast agents | EPIX MEDICAL, INC. A DELAWARE CORPORATION | 2005-04-07 | — | — | US | disclosed |
| EP-1420681-A2 | PEPTIDE-BASED MULTIMERIC TARGETED CONTRAST AGENTS | Epix Medical, Inc. (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20030216320-A1 | Peptide-based multimeric targeted contrast agents | Factor 1A, LLC | 2003-11-20 | — | — | US | disclosed |
| US-20030180222-A1 | Peptide-based multimeric targeted contrast agents | EPIX PHARMACEUTICALS, INC. | 2003-09-25 | — | — | US | disclosed |
| WO-2003011115-A2 | PEPTIDE-BASED MULTIMERIC TARGETED CONTRAST AGENTS | EPIX MEDICAL, INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030180222-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | ALDH1A1 4848/4885MAPK1 2622/4885L3MBTL1 1784/4885 |
| US-20060039861-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | ALDH1A1 4848/4885MAPK1 2622/4885L3MBTL1 1784/4885 |
| US-20070185311-A1 | Peptide-Based Multimeric Targeted Contrast Agents | NGLY1, IAPP, NPPA | ALDH1A1 4848/4885MAPK1 2622/4885L3MBTL1 1784/4885 |
| US-20050074411-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | ALDH1A1 4848/4885MAPK1 2622/4885L3MBTL1 1784/4885 |
| US-20030216320-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | ALDH1A1 4848/4885MAPK1 2622/4885L3MBTL1 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.